Interestingly, our study revealed a cell-specific reduction in FGFBP1 levels in lymphoma cells upon B4 treatment, with negligible effects on FGF signaling molecules like FGF1, FGF2, FGF3, FGF7, FGF10, FGF22, FGFR2, HSPG2, PROM1, and TBX21. This evidence concerns the gene HSPG2 and lymphoma.